BDX vs CERS
BDX: BD is a leading global medical technology company providing essential medical devices, diagnostic systems, and laboratory solutions to healthcare providers and researchers worldwide. CERS: Cerus is a developer of blood safety technologies, specifically pathogen reduction systems designed to protect the blood supply from transfusion-transmitted infections.
Side-by-side fundamentals
| Metric | BDX | CERS | Edge |
|---|---|---|---|
| Price as of 2026-07-31 close | $165.62 | $2.15 | |
| Market cap as of 2026-08-03 | $45.6B | $433M | |
| P/E as of 2026-08-03 | 42.05 | n/a | |
| PEG as of 2026-08-03 | -24.04 | n/a | |
| Net margin as of 2026-08-03 | +5.3% | -3.9% | BDX higher |
| Gross margin as of 2026-08-03 | +47.0% | +58.4% | CERS higher |
| Operating margin as of 2026-08-03 | +10.2% | -1.3% | BDX higher |
| ROE as of 2026-08-03 | +4.5% | -15.4% | BDX higher |
| ROA as of 2026-08-03 | +2.1% | -4.4% | BDX higher |
| Debt / equity as of 2026-08-03 | 0.72 | 1.26 | BDX lower |
| Revenue growth (YoY) as of 2026-08-03 | +2.4% | +18.4% | CERS higher |
| Revenue CAGR (3y) SEC XBRL | +5.0% | +7.5% | CERS higher |
| Dividend yield as of 2026-08-03 | +2.5% | n/a | |
| Dividend streak (yrs) SEC XBRL | 5 | n/a | |
| Beta as of 2026-08-03 | 0.44 | 1.66 | |
| 1-year return as of 2026-07-31 close | +18.2% | +68.0% | CERS higher |
Fundamentals: market data, as of 2026-08-03. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-07-31.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & market data, shown with their as-of date; "Edge" cells are a pure numeric comparison, not a recommendation.